MALAT1 and posterior cortical atrophy: According to preclinical research by Chou et al., Cis- and Carboplatin-mediated suppression of the MALAT1/SF2 RNA splicing complex may lead to degradation of AR-V7, potentially re-sensitizing AR-V7 expressing PCa cells to enzalutamide [49].